Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity

Jiajia Zhang, Zhicheng Ji, Kellie Smith

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Anti-tumor T cells are the soldiers in the body's war against cancer. Effector T cells can detect and eliminate cells expressing their cognate antigen via activation through engagement of the T cell receptor (TCR) with its cognate peptide:MHC complex. Owing to the recent success of immunotherapy in the treatment of many different cancer types, research efforts have shifted toward identifying and tracking anti-tumor T cell responses upon treatment in cancer patients. While traditional methods, such as ELISpot and flow cytometric intracellular staining have had limited success, likely owing to the inability to get viable biospecimens or the lower magnitude of tumor-specific T cell responses relative to virus-specific responses, new techniques that utilize next generation sequencing enable T cell response tracking independent of cytokine production or cell viability. The TCR, which confers T cell antigen-specificity, can be used as a molecular barcode to track T cell clonotypic dynamics across biological compartments and over time in cancer patients undergoing treatment. Because this method does not require viable cells, these T cell clonotypes can also be tracked in archival tumor tissue and flash frozen cell pellets. While exciting, quantitative TCR sequencing (TCRseq) technologies have been met with the conundrum of how to properly analyze and interpret the data. Here we provide a comprehensive guide on how to acquire, analyze, and interpret TCRseq data, as well as special considerations that should be taken prior to experimental setup.

Original languageEnglish (US)
Title of host publicationMethods in Enzymology
PublisherAcademic Press Inc.
DOIs
StateAccepted/In press - Jan 1 2019

Publication series

NameMethods in Enzymology
ISSN (Print)0076-6879
ISSN (Electronic)1557-7988

Fingerprint

T-cells
T-Cell Antigen Receptor
Tumors
Immunity
T-Lymphocytes
Neoplasms
Cells
Cell Tracking
Patient treatment
T-Cell Antigen Receptor Specificity
Antigens
Viral Tumor Antigens
Military Personnel
Viruses
Immunotherapy
Cell Survival
Therapeutics
Chemical activation
Tissue
Staining and Labeling

Keywords

  • Antigen specificity
  • Bioinformatics
  • Cancer
  • Immunogenomics
  • T cell receptor
  • T cells
  • TCR sequencing

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Zhang, J., Ji, Z., & Smith, K. (Accepted/In press). Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity. In Methods in Enzymology (Methods in Enzymology). Academic Press Inc.. https://doi.org/10.1016/bs.mie.2019.08.006

Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity. / Zhang, Jiajia; Ji, Zhicheng; Smith, Kellie.

Methods in Enzymology. Academic Press Inc., 2019. (Methods in Enzymology).

Research output: Chapter in Book/Report/Conference proceedingChapter

Zhang, J, Ji, Z & Smith, K 2019, Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity. in Methods in Enzymology. Methods in Enzymology, Academic Press Inc. https://doi.org/10.1016/bs.mie.2019.08.006
Zhang J, Ji Z, Smith K. Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity. In Methods in Enzymology. Academic Press Inc. 2019. (Methods in Enzymology). https://doi.org/10.1016/bs.mie.2019.08.006
Zhang, Jiajia ; Ji, Zhicheng ; Smith, Kellie. / Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity. Methods in Enzymology. Academic Press Inc., 2019. (Methods in Enzymology).
@inbook{10ac0e3a53cd4c309d487b64d957aad6,
title = "Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity",
abstract = "Anti-tumor T cells are the soldiers in the body's war against cancer. Effector T cells can detect and eliminate cells expressing their cognate antigen via activation through engagement of the T cell receptor (TCR) with its cognate peptide:MHC complex. Owing to the recent success of immunotherapy in the treatment of many different cancer types, research efforts have shifted toward identifying and tracking anti-tumor T cell responses upon treatment in cancer patients. While traditional methods, such as ELISpot and flow cytometric intracellular staining have had limited success, likely owing to the inability to get viable biospecimens or the lower magnitude of tumor-specific T cell responses relative to virus-specific responses, new techniques that utilize next generation sequencing enable T cell response tracking independent of cytokine production or cell viability. The TCR, which confers T cell antigen-specificity, can be used as a molecular barcode to track T cell clonotypic dynamics across biological compartments and over time in cancer patients undergoing treatment. Because this method does not require viable cells, these T cell clonotypes can also be tracked in archival tumor tissue and flash frozen cell pellets. While exciting, quantitative TCR sequencing (TCRseq) technologies have been met with the conundrum of how to properly analyze and interpret the data. Here we provide a comprehensive guide on how to acquire, analyze, and interpret TCRseq data, as well as special considerations that should be taken prior to experimental setup.",
keywords = "Antigen specificity, Bioinformatics, Cancer, Immunogenomics, T cell receptor, T cells, TCR sequencing",
author = "Jiajia Zhang and Zhicheng Ji and Kellie Smith",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/bs.mie.2019.08.006",
language = "English (US)",
series = "Methods in Enzymology",
publisher = "Academic Press Inc.",
booktitle = "Methods in Enzymology",

}

TY - CHAP

T1 - Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity

AU - Zhang, Jiajia

AU - Ji, Zhicheng

AU - Smith, Kellie

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Anti-tumor T cells are the soldiers in the body's war against cancer. Effector T cells can detect and eliminate cells expressing their cognate antigen via activation through engagement of the T cell receptor (TCR) with its cognate peptide:MHC complex. Owing to the recent success of immunotherapy in the treatment of many different cancer types, research efforts have shifted toward identifying and tracking anti-tumor T cell responses upon treatment in cancer patients. While traditional methods, such as ELISpot and flow cytometric intracellular staining have had limited success, likely owing to the inability to get viable biospecimens or the lower magnitude of tumor-specific T cell responses relative to virus-specific responses, new techniques that utilize next generation sequencing enable T cell response tracking independent of cytokine production or cell viability. The TCR, which confers T cell antigen-specificity, can be used as a molecular barcode to track T cell clonotypic dynamics across biological compartments and over time in cancer patients undergoing treatment. Because this method does not require viable cells, these T cell clonotypes can also be tracked in archival tumor tissue and flash frozen cell pellets. While exciting, quantitative TCR sequencing (TCRseq) technologies have been met with the conundrum of how to properly analyze and interpret the data. Here we provide a comprehensive guide on how to acquire, analyze, and interpret TCRseq data, as well as special considerations that should be taken prior to experimental setup.

AB - Anti-tumor T cells are the soldiers in the body's war against cancer. Effector T cells can detect and eliminate cells expressing their cognate antigen via activation through engagement of the T cell receptor (TCR) with its cognate peptide:MHC complex. Owing to the recent success of immunotherapy in the treatment of many different cancer types, research efforts have shifted toward identifying and tracking anti-tumor T cell responses upon treatment in cancer patients. While traditional methods, such as ELISpot and flow cytometric intracellular staining have had limited success, likely owing to the inability to get viable biospecimens or the lower magnitude of tumor-specific T cell responses relative to virus-specific responses, new techniques that utilize next generation sequencing enable T cell response tracking independent of cytokine production or cell viability. The TCR, which confers T cell antigen-specificity, can be used as a molecular barcode to track T cell clonotypic dynamics across biological compartments and over time in cancer patients undergoing treatment. Because this method does not require viable cells, these T cell clonotypes can also be tracked in archival tumor tissue and flash frozen cell pellets. While exciting, quantitative TCR sequencing (TCRseq) technologies have been met with the conundrum of how to properly analyze and interpret the data. Here we provide a comprehensive guide on how to acquire, analyze, and interpret TCRseq data, as well as special considerations that should be taken prior to experimental setup.

KW - Antigen specificity

KW - Bioinformatics

KW - Cancer

KW - Immunogenomics

KW - T cell receptor

KW - T cells

KW - TCR sequencing

UR - http://www.scopus.com/inward/record.url?scp=85071685539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071685539&partnerID=8YFLogxK

U2 - 10.1016/bs.mie.2019.08.006

DO - 10.1016/bs.mie.2019.08.006

M3 - Chapter

C2 - 31727253

AN - SCOPUS:85071685539

T3 - Methods in Enzymology

BT - Methods in Enzymology

PB - Academic Press Inc.

ER -